Skip to main content
SpringerLink
Log in

Evidence Based Management of Acute Myocardial Infarction

  • Chapter
Resource Utilization in Cardiac Disease

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 216))

  • 49 Accesses

Abstract

Prior to the use of thrombolytic therapy, therapy for acute myocardial infarction consisted of pain relief, electrocardiographic and blood pressure monitoring, treatment of ventricular arrhythmias, and the management of acute heart failure. The general measures of treatment are listed in Table 1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chatterjee K, Swan H, Kaushik V, et al. Effects of vasodilator therapy for severe pump failure in acute myocardial infarction on short-term and late prognosis. Circulation 1976; 53(5): 797–802.

    PubMed  CAS  Google Scholar 

  2. Cohn J, Johnson G, Ziesche S, et al. A comparison of Enalapril with Hydralazine-Isosorbide Dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine 1991; 325:303–310.

    PubMed  CAS  Google Scholar 

  3. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive hart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. New England Journal of Medicine 1987; 316:1429–1435.

    Google Scholar 

  4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 1991; 325:293–302.

    Google Scholar 

  5. Cohn J, Archibald D, Phil M, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. New England Journal of Medicine 1986; 314:1547–1552.

    PubMed  CAS  Google Scholar 

  6. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per to Studio della Soprawivenza nell’Infarto Miocardico. Lancet 1994; 343:1115–1122.

    Google Scholar 

  7. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. New England Journal of Medicine 1992; 327:669–677.

    PubMed  CAS  Google Scholar 

  8. Tillet W, Gamer R. The fibrinolytic activity of streptococci. J Exp Med 1933; 58:485.

    Google Scholar 

  9. Fletcher A, Sherry S, Alkjaersig M, et al. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958; 71:287.

    PubMed  CAS  Google Scholar 

  10. Wasserman A, Ross A. Coronary thrombolysis. Current Problems in Cardiology 1989 XIV: 1–54.

    Google Scholar 

  11. ISIS-3. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival). Lancet 1992; 339:753–770.

    Google Scholar 

  12. GUSTO Investigators. An international randomized trial comparing fourthrombolytic strategies for acute myocardial infarction. New England Journal of Medicine 1993; 329:673–682.

    Google Scholar 

  13. Anderson J, Marshall H, Bray B. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. New England Journal of Medicine 1983; 308:1312.

    PubMed  CAS  Google Scholar 

  14. Chapman RA. Control of cardiac contractility at the cellular level. American Journal of Physiology 1983; 245:H535–H552.

    PubMed  CAS  Google Scholar 

  15. Furberg C. Clinical value of intracoronary streptokinase. American Journal of Cardiology 1984; 53:626.

    PubMed  CAS  Google Scholar 

  16. Ganz W, Buchbinder N, Marcus H, et al. Intracoronary thrombolysis in evolving myocardial infarction. American Heart J 1981; 101:4.

    CAS  Google Scholar 

  17. Kennedy J, Gensini G, Timmis G, Maynard C. Acute myocardial infarction treated with intracoronary streptokinase A report of the society for cardiac angiography. American Journal of Cardiology 1985; 55:871–877.

    PubMed  CAS  Google Scholar 

  18. Kennedy J, Ritchie J, Davis K, et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. New England Journal of Medicine 1983; 309:1477.

    PubMed  CAS  Google Scholar 

  19. Leiboff R, Katz R, Wasserman A, et al. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. American Journal of Cardiology 1984; 53:404.

    PubMed  CAS  Google Scholar 

  20. Dalen J, Gore J, Braunwald E, et al. Six-and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. American Journal of Cardiology 1988; 62:179–185.

    PubMed  CAS  Google Scholar 

  21. White H, Rivers J, Maslowski A, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. New England Journal of Medicine 1989; 320:817–821.

    PubMed  CAS  Google Scholar 

  22. Verstraete M, Bernard B, Bory M, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985; 1:842.

    PubMed  CAS  Google Scholar 

  23. Anderson J, Rothbard R, Hackworthy R. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex APSAC in acute myocardial infarction Controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 1988; 11:1153.

    PubMed  CAS  Google Scholar 

  24. APSAC Multicenter Investigators. Multicenter Reperfusion Trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 1988; 11:1153–1163.

    Google Scholar 

  25. GISSI. Long-term effects of intravenous thrombolysis in acute myocardial infarction final report of the GISSI study. Lancet 1987; 2:871–874.

    Google Scholar 

  26. ISIS. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2(1)349–360.

    Google Scholar 

  27. Serruys P, Simoons M, Suryappanata H, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986; 7:729–742.

    PubMed  CAS  Google Scholar 

  28. Timmis A, Griffin B, Crick J, et al. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol 1987; 10:205.

    PubMed  CAS  Google Scholar 

  29. Verstraete M, Bernard R, Bory M, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 2:965.

    PubMed  CAS  Google Scholar 

  30. White H, Norris R, Brown M, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. New England Journal of Medicine 1987; 317:850–855.

    PubMed  CAS  Google Scholar 

  31. Wilcox R, Lippe GVD, Olsson C, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (Anglo-Scandinavian Study of Early Thrombolysis [ASSET]). Lancet 1988; 2:525–530.

    PubMed  CAS  Google Scholar 

  32. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397–401.

    Google Scholar 

  33. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65–71.

    Google Scholar 

  34. EMERAS Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342:767–772.

    Google Scholar 

  35. Fibrinolytic Therapy Trailists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994 343:311–322.

    Google Scholar 

  36. Ryan TJ, Anderson JL, Antman EM, Braniff BA, et al. ACC/AHA guidelines for the management of patients with aucte myocardial infarction: Executvie summary. Circulation 1996; 94:2341–2350.

    PubMed  CAS  Google Scholar 

  37. Ryan TJ, Anderson JL, Antman EM, Braniff BA, et al. ACC/AHA guidelines for the management of patients with aucte myocardial infarction. JACC 1996: 28(5): 1328–1428.

    PubMed  CAS  Google Scholar 

  38. Bouten M, Simoons M, Hartman J, et al. Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction. European Heart Journal 1992 13:925–931.

    PubMed  CAS  Google Scholar 

  39. Weaver J, Cerqueira M, Hallstrom P, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. Journal of American Medical Association 1993 270:1211–1216.

    CAS  Google Scholar 

  40. SCATI Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989, 2:182–186.

    Google Scholar 

  41. Hsia J, Hamilton W, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. New England Journal of Medicine 1990 323:1436–1437.

    Google Scholar 

  42. O’Connor C, Meese R, Carneyl R. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) 1. J AmColl Cardiol 1994; 23:11–18.

    Google Scholar 

  43. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986 8498:57–66.

    Google Scholar 

  44. Homer S. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality Meta-analysis of magnesium in acute myocardial infarction. Circulation 1992; 86:774–779.

    Google Scholar 

  45. Woods K, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339:1553–1558.

    PubMed  CAS  Google Scholar 

  46. ISIS-4 Collaborative Group. Randomised study of intravenous magnesium in over 50,000 patients with suspected acute myocardial infarction, abstracted. Circulation 1993; 88(Suppl I):I–292.

    Google Scholar 

  47. Ridker P, Hebert P, Fuster V, Hennekens C. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993 341:1574–1577.

    PubMed  CAS  Google Scholar 

  48. Jeremy R, Hackworthy R, Bautovich G, et al. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J AmColl Cardiol 1987; 9:989–995.

    CAS  Google Scholar 

  49. White H, Cross D, Elliott J, et al. Long-term prognostic importance of patency of the infarctrelated coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89:59–67.

    Google Scholar 

  50. Guerci A, Gerstenblith G, Brinker J, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. New England Journal of Medicine 1987, 317:1613–1618.

    PubMed  CAS  Google Scholar 

  51. Topol E. Coronary angioplasty for acute myocardial infarction. Annals of Internal Medicine 1988; 109:970–980.

    PubMed  CAS  Google Scholar 

  52. Topol E, Califf R, George B, et al. Thrombolysis and Angioplasty in Myocardial Infarction Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. New England Journal of Medicine 1987; 317(10)581–588.

    PubMed  CAS  Google Scholar 

  53. Grines C, Browne K, Marco J, et al. A comparison of immediate angioplasty withthombolytic therapy for acute myocardial infarction. New England Journal of Medicine 1993 328:673–679.

    PubMed  CAS  Google Scholar 

  54. Gibbons R, Holmes D, Reeder G, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. New England Journal of Medicine 1993 328:685–691.

    PubMed  CAS  Google Scholar 

  55. Zijlstra F, Boer JD, Hoorntje C, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. New England Journal of Medicine 1993; 328:680–684.

    PubMed  CAS  Google Scholar 

  56. Reeder G, Bailey K, Gersh B, et al. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction A randomized prospective trial. Mayo Clinical Proceedings 1994 69:5–12.

    CAS  Google Scholar 

  57. Bigger JT, Fleiss JL, Kleiger R, et al. The relationship among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250–258.

    PubMed  Google Scholar 

  58. Bigger Jr J, Fleiss J, Rolnitzky L, Multicenter Post-Infarction Research Group. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. American Journal of Cardiology 1986 58:1151–1160.

    PubMed  Google Scholar 

  59. Hallstrom A, Bigger J, Roden D, et al. Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. J AmColl Cardiol 1992; 20:259–264.

    CAS  Google Scholar 

  60. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. New England Journal of Medicine 1983; 309:331–336.

    Google Scholar 

  61. De Feyter P, VanFenige M, Dighten D. Prognostic value of exercise testing, coronary angiography and left ventriculography six to eight weeks after myocardial infarction. Circulation 1982; 66:527–536.

    PubMed  Google Scholar 

  62. DeBusk R. Evaluation of patients after recent acute myocardial infarction. Annals of Internal Medicine 1989; 110:485–488.

    Google Scholar 

  63. Fioretti P, Brower R, Simmons M, et al. Prediction of mortality during the first year after acute myocardial infarction from clinical variables and stress test at hospital discharge. American Journal of Cardiology 1985; 55:1313–1318.

    PubMed  CAS  Google Scholar 

  64. Krone R, Dwyer E, Greenberg H, et al. Risk stratification in patients with first non-q wave infarction: limited value of the early low level exercise test after uncomplicated infarcts. J Am Coll Cardiol 1989; 14:31–37.

    PubMed  CAS  Google Scholar 

  65. Krone R, Gillespie J, Weld F, et al. Low-level exercise testing after myocardial infarction: usefulness in enhancing clinical risk stratification. Circulation 1985; 71:80–89.

    PubMed  CAS  Google Scholar 

  66. Madsen E, Gilpin E, Ahnvee S. Prediction of functional capacity and use of exercise testing for predicting risk after acute myocardial infarction. American Journal of Cardiology 1985; 56:839–845.

    Google Scholar 

  67. Theroux P, Waters D, Halphen C, et al. Prognostic value of exercise testing soon after myocardial infarction. New England Journal of Medicine 1979; 301:341–345.

    PubMed  CAS  Google Scholar 

  68. Weld F, Chu K, Bigger J, Rolnitzky L. Risk stratification with low level exercise testing 2 weeks after acute myocardial infarction. Circulation 1981; 64:306–314.

    PubMed  CAS  Google Scholar 

  69. Williams W, Nair R, Higginson L, et al. Comparison of clinical and treadmill variables for the prediction of outcome after myocardial infarction. J AmColl Cardiol 1984; 4:477–486.

    CAS  Google Scholar 

  70. Buda A, Dubbin J, Mac Donald I, et al. Spontaneous changes in thallium-201 myocardial perfusion imaging after myocardial infarction. American Journal of Cardiology 1982 50:1271–1278.

    Google Scholar 

  71. Gibson R, Beller G, Gheorghiade M. The prevalence and clinical significance of residual myocardial ischemia two weeks after uncomplicated non Q-wave infarction A prospective natural history study. Circulation 1986; 73(6)1186–1198.

    PubMed  CAS  Google Scholar 

  72. Gibson R, Watson D, Graddock G, et al. Prediction of cardiac events after uncomplicated myocardial infarction: A prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation 1983; 68:321–336.

    PubMed  CAS  Google Scholar 

  73. Hung J, Gordon E, Houston N, et al. Changes in rest and exercise myocardial perfusion and left ventricular function 3 to 26 weeks after clinically uncomplicated acute myocardial infarction. American Journal of Cardiology 1984; 54:943–950.

    PubMed  CAS  Google Scholar 

  74. Hung J, Goris M, Nash E, et al. Comparative value of maximal treadmill testing, exercise thallium myocardial perfusion scintigraphy and exercise radionuclide ventriculography for distinguishing high-and low-risk patients soon after acute myocardial infarction. American Journal of Cardiology 1984; 53:1221–1227.

    PubMed  CAS  Google Scholar 

  75. Tilkemeier P, Guiney T, LaRaia P, Boucher C. Prognostic value of predischarge low-level exercise thallium testing after thrombolytic treatment of acute myocardial infarction. American Journal of Cardiology 1990; 66:1203–1207.

    PubMed  CAS  Google Scholar 

  76. Wilson W, Gibson R, Nygaard T. Acute myocardial infarction associated with single vessel coronary artery disease: An analysis of clinical outcome and the prognostic importance of vessel patency and residual ischemia myocardium. J AmColl Cardiol 1988; 11:223–234.

    CAS  Google Scholar 

  77. Hamm L, Crow R, Stuli G et al. Safety and characteristics of exercise testing early after acute myocardial infarction. American Journal of Cardiology 1989; 63:1193–1197.

    PubMed  CAS  Google Scholar 

  78. Jain A, Myers H, Sapin P, O’Rourke R. Superiority and safety of maximal exercise testing early after myocardial infarction. J AmColl Cardiol 1993; 21(suppl A):98A.

    Google Scholar 

  79. Juneau M, Colles P, Theroux P. Symptom-limited versus low level exercise testing before hospital discharge after myocardial infarction. J AmColl Cardiol 1992; 20:927–933.

    CAS  Google Scholar 

  80. Botvinick E, Dae M. Dipyridamole perfusion scintigraphy. Semin Nucl Med 1991; XXI:242–265.

    Google Scholar 

  81. Gimple L, Hutter A, Guiney T, Boucher C. Prognostic utility of predischarge dipyridamole-thallium imaging compared to predischarge submaximal exercise electrocardiography and maximal exercise thallium imaging after uncomplicated acute myocardial infarction. American Journal of Cardiology 1989; 64:1243–1248.

    PubMed  CAS  Google Scholar 

  82. Marzullo P, Parodi O, Reisenhofer B, et al. Value of rest thallium-201/technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. American Journal of Cardiology 1993; 71:166–172.

    PubMed  CAS  Google Scholar 

  83. Dilsizian V, Bonow R. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 1993; 87:1–20.

    PubMed  CAS  Google Scholar 

  84. Barilla F, Gheorghiade M, Alam M, et al. Low-dose dobutamine in patients with acute myocardial infarction identifies viable but not contractile myocardium and predicts the magnitude of improvement in wall motion abnormalities in response to coronary revascularization. American Heart J 1991; 122:1522–1531.

    CAS  Google Scholar 

  85. Berman D, Kiat H, Van Train K, et al. Technetium 99m sestamibi in the assessment of chronic coronary artery disease. Seminars in Nuclear Medicine 1991; 21:190–212.

    PubMed  CAS  Google Scholar 

  86. Cuocolo A, Pace L, Ricciardelli B, et al. Identification of viable myocardium in patients with chronic coronary artery disease Comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile. Journal of Nuclear Medicine 1992;33:505–511.

    Google Scholar 

  87. ACC/AHA Task Force. Guidelines for the early management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). Journal of the American College of Cardiology 1990; 16:249–292.

    Google Scholar 

  88. SWIFT Trial Study Group. SWIFT trial of delayed elective intervention vs conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. British Medical Journal 1991; 302:555–560.

    Google Scholar 

  89. TIMIII Investigators. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. J AmColl Cardiol 1991; 17:1007–1016.

    Google Scholar 

  90. Ross R, Gilpin E, Madsen E, et al. A decision scheme for coronary angiography after acute myocardial infarction. Circulation 1989; 79:292–303.

    PubMed  Google Scholar 

  91. Shenasa M, Fetsch T, Martinez-Rubio A, et al. Signal averaging in patients with coronary artery disease: How helpful is it? Journal of Cardiovascular Electrophysiology 1993; 4:609–626.

    PubMed  CAS  Google Scholar 

  92. O’Quin R, Marini JJ. Pulmonary artery occlusion pressure Clinical physiology, measurement and interpretation. American Revision Respiratory Disease 1983; 128:319–326.

    Google Scholar 

  93. Moss A, DeCamilla J, Davis H. Cardiac death in the first 6 months after myocardial infarction Potential for mortality reduction in the early post-hospital period. American Journal of Cardiology 1977; 39:816–820.

    PubMed  CAS  Google Scholar 

  94. Mukharji J, Rude R, Pool W. Risk factors for sudden death after acute myocardial infarction Two year follow-up. American Journal of Cardiology 1984; 54:31–36.

    PubMed  CAS  Google Scholar 

  95. Hutter A, DeSanctis R, Flynn T, Yeatman L. Nontransmural myocardial infarction A comparison of hospital and late clinical course of patients with that of matched patients with transmural anterior and transmural inferior myocardia infarction. American Journal of Cardiology 1981; 48:595–602.

    PubMed  Google Scholar 

  96. Kao W, Khaja F, Goldstein S, Gheorghiade M. Cardiac event rate after non-q-wave acute myocardial infarction and the significance of its anterior location. American Journal of Cardiology 1989;64:1236–1242.

    PubMed  CAS  Google Scholar 

  97. Schechtman K, Capone R, Kleiger R, et al. Risk stratification of patients with non-Q wave myocardial infarction. The critical role of ST segment depression. Circulation 1989 80:1148–1158.

    PubMed  CAS  Google Scholar 

  98. Schechtman K, Kleiger R, Boden W, et al. The relationship between 1-year mortality and infarct location in patients with non-Q wave myocardial infarction. American Heart J 1992; 123:1175–1181.

    CAS  Google Scholar 

  99. Anderson J, Karagounis L, Becker L, et al. TIMI perfusion Grade 3 but not Grade 2 results in improved outcome after thrombolysis for myocardial infarction: Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829–1839.

    PubMed  CAS  Google Scholar 

  100. Vogt A, Essen RV, Tobbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction Retrospective analysis of four German multicenter studies. J AmColl Cardiol 1993; 21:1391–1395.

    CAS  Google Scholar 

  101. Gohike H, Heim E, Roskamm H. Prognostic importance of collateral flow and residual coronary stenosis of the myocardial infarction artery after anterior wall Q-wave acute myocardial infarction. American Journal of Cardiology 1991; 67:1165–1169.

    Google Scholar 

  102. Rogers W, Hood W, Mantle J, et al. Return of left ventricular function after reperfusion in patients with myocardial infarction: Importance of subtotal stenoses or intact collaterals. Circulation 1984; 69:33.

    Google Scholar 

  103. β-blocker Heart Attack Research Group. A randomized trial of propranololin patients with acute myocardial infarction. Journal of American Medical Association 1982, 247:1707–1714.

    Google Scholar 

  104. Hampton J. Secondary prevention of acute myocardial infarction with beta-blocking agents and calcium antagonists. American Journal of Cardiology 1990; 66:3C–8C.

    PubMed  CAS  Google Scholar 

  105. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metroprolol in acute myocardial infarction: A double-blind randomised trial. Lancet 1981; 2:823.

    PubMed  CAS  Google Scholar 

  106. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine 1981; 304:801–807.

    Google Scholar 

  107. Yusuf S, Peto R, Lewis J et al. Betablockade during and after myocardial infarction An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335–371.

    PubMed  CAS  Google Scholar 

  108. Multicenter Diltiazem Post-Infarction Research Group. The effect of diltiazem on mortality and reinfarction after acute myocardial infarction. New England Journal of Medicine 1988; 319:385–392.

    Google Scholar 

  109. (SPRINT) Secondary Prevention Reinfarction Nifedipine Trial. A randomized intervention trial of nifedipine in patients with acute myocardial infarction. European Heart Journal 1988; 9:354–364.

    Google Scholar 

  110. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the cooperative new Scandinavian enalapril survival study II (Consensus II). New England Journal of Medicine 1992; 327:678–684.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rush-Presbyterian-St Luke’s Medical Center, Chicago, IL, USA

    James E. Calvin MD

Authors
  1. James E. Calvin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Cardiology, Department of Medicine, Rush-Presbyterian-St. Luke’s Medical Center, Rush Medical School, 1653 West Congress Parkway, Chicago, IL, 60612-3833, USA

    Lloyd W. Klein M.D.  & James E. Calvin M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Calvin, J.E. (1999). Evidence Based Management of Acute Myocardial Infarction. In: Klein, L.W., Calvin, J.E. (eds) Resource Utilization in Cardiac Disease. Developments in Cardiovascular Medicine, vol 216. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5023-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5023-5_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7282-0

  • Online ISBN: 978-1-4615-5023-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation